title: [Immunoclinical, molecular and immunopathologic approach to chronic viral hepatitis. Therapeutic considerations].
abstract: Through a pilot study which includes a clinical, molecular and immunopathological approach to the chronic Hepatitis induced by HBV or by HCV, we determined that 66% of HBsAg carriers are in the "non viremic" phase. The positive HBeAg "viremic" carriers showed HBV-DNA quantitation which varies between > 50 pg to > 100 pg. Both types of carries are infected with the "wild" type HBV. Each subgroup of positive surface antigemia carriers demonstrated a differential immunopathological response. So far, 96% of the HCV carriers investigated, showed HCV-RNA associated to repeatedly positive anti-HCV antibodies. Those patients with increased ALT values uniformly expressed liver histopathological signs of inflammation caused by HCV; demonstrating also the presence of peripheral blood mononuclear cells infected with HCV. At the present, the genotypes investigation indicates a predominance of HCV genotype II (1b). Autoimmune phenomenons associated to HCV have been detected only in 3 patients. The therapeutic approach with interferon alpha applied to the HCV infection preliminary showed similar results to those reported worldwide. Currently, a comprehensive approach to the chronic HBV and chronic HCV infections requires the application of Immunochemistry, Molecular Biology and Cellular Immunology combined technologies.
authors.affiliation: Instituto de Inmunologia, Facultad de Medicina, UCV.
authors.forename: I V
authors.initials: IV
authors.lastname: Machado
authors.forename: L
authors.initials: L
authors.lastname: Deibis
authors.forename: E
authors.initials: E
authors.lastname: Risquez
authors.forename: P
authors.initials: P
authors.lastname: Tassinari
authors.forename: M E
authors.initials: ME
authors.lastname: Zabaleta
authors.forename: F I
authors.initials: FI
authors.lastname: Toro
authors.forename: M L
authors.initials: ML
authors.lastname: Baroja
authors.forename: J
authors.initials: J
authors.lastname: Corado
authors.forename: M E
authors.initials: ME
authors.lastname: Ruiz
authors.forename: L
authors.initials: L
authors.lastname: Longart
mesh_terms: D000328:Adult; D002985:Clinical Protocols; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics; D006509:Hepatitis B / Q000175:diagnosis / Q000628:therapy; D006515:Hepatitis B virus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis / Q000628:therapy; D006521:Hepatitis, Chronic / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007159:Immunologic Tests; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins
chemical_list: D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins
vernacular_title: Abordaje inmunoclinico, molecular e inmunopatológico de la hepatitis crónica viral. Consideraciones terapeuticas.